Tag Archive for: COVID-19 vaccine

According to brokerage Oppenheimer, Moderna could have five products on the market by 2026.

Pfizer, BioNTech, and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome’s lawsuit accusing the COVID-19 vaccine makers of infringing a patent related to messenger RNA technology.

Around 4 million Americans received the updated COVID-19 shots in September, according to the U.S. Department of Health and Human Services (HHS), even as some people have found it difficult to book vaccination appointments or find the vaccines at no cost.

Moderna on Wednesday said its combination vaccine to protect against both COVID-19 and influenza generated a strong immune response compared to individual shots for the viruses in an early-stage study.

The U.S. Food and Drug Administration said on Tuesday it authorized an updated version of Novavax’s COVID-19 vaccine for emergency use in individuals aged 12 years and older, and the company’s shares closed 8% higher.

Hungarian scientist Katalin Kariko and U.S. colleague Drew Weissman, who met in line for a photocopier before making mRNA molecule discoveries that paved the way for COVID-19 vaccines, won the 2023 Nobel Prize for Medicine on Monday.

The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending a decision by the federal patent court on a lawsuit filed by BioNTech.

The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.

The company stated that its flu vaccine had generated a stronger immune response against all four A and B strains of the virus compared to traditional flu shots in a late-stage trial. Moderna also announced it was scaling down manufacturing of its COVID-19 vaccine, an updated version of which was approved this week by U.S. regulators, to align with lower post-pandemic demand and help the company sooner hit its target of 75% to 80% gross margin growth.

China’s CanSino Biologics, which recently announced a contract manufacturing deal to support AstraZeneca’s messenger RNA (mRNA) technology vaccine program, is in talks with more firms on similar deals, its CEO said, as it seeks new revenue streams to make up for plummeting COVID vaccine demand.